Monographie - Caffeine citrate - Stabilis 4.0

Viimeisin päivitys :
03/05/2024

Hengitysstimulantit

Caffeine citrate

Injektioneste

Oraaliliuos

Stabilius liuoksessa

Stabilius seoksissa

Tekijät, jotka vaikuttavat stabiliuteen

Yhteensopivuus

Antotapa

Viitteet

Pdf

Kemiallinen rakenne

Kauppanimi

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cafcit	Yhdysvallat
Cafeina 25% Bioquim	Argentiina
Cafeina citrato	Espanja
Cafeina Fada	Argentiina
Cafeine citrate Biomed	New Zealand
Cafeine Sterop	Belgia
Cafeinnova	Kolumbia
Caffeinospire	Egypti
Cafirate	Intia
Citrate de caféine Cooper	Ranska
Peyona oral y para perfusion	Espanja
Peyona oral/parenteral	Romania, Saksa, Turkki

Viitteet

Injektioneste

Viitteet : Caffeine citrate

	Tyyppi	Julkaisu
43	Lehti	Fraser BD, Berod T, Whitney HAK. Stability of caffeine citrate injection in polypropylene syringes at room temperature. Am J Health-Syst Pharm 1997 ; 54: 1106-1108.
318	Lehti	Donnelly RF, Tirona RG. Stability of citrated caffeine injectable solution in glass vials. Am J Hosp Pharm 1994 ; 51: 512-514.
691	Lehti	Nahata MC, Zingarelli JR, Durell DE. Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions. J Clin Pharm Ther 1989 ; 14: 53-55.
1802	Lehti	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
2087	Lehti	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
3379	Lehti	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3644	Laboratorio	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3976	Lehti	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4319	Lehti	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Lehti	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Lehti	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4543	Lehti	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Lehti	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Lehti	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales